Active — Not RecruitingPhase 2

Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer

China33 participantsStarted 2026-02-26

Plain-language summary

This is a single-arm interventional study targeting patients with initially unresectable MSS-type advanced colorectal cancer with liver and/or lung and peritoneal metastasis. Patients will receive lymph node-sparing modified short-course radiotherapy combined with tislelizumab, CAPOX chemotherapy, and bevacizumab targeted therapy, aiming to explore the tumor reactivity and safety of modified short-course radiotherapy combined with immunotherapy and first-line treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Hemoglobin ≥ 6.0 mmol/L,
✓. Absolute neutrophil count ≥ 1.5 ×10⁹/L,
✓. Platelet count ≥ 100 ×10⁹/L;
✓. Renal function: serum creatinine ≤ 1.5 × ULN and creatinine clearance ≥ 30 mL/min;
✓. Hepatic function: serum bilirubin ≤ 2 × ULN, serum transaminases ≤ 5 × ULN. 9. No contraindications to surgery.

Exclusion criteria

✕. NYHA class ≥ II heart failure;
✕. unstable angina;
✕. myocardial infarction within 1 year;
✕. clinically significant supraventricular or ventricular arrhythmias that are uncontrolled or poorly controlled despite intervention.

What they're measuring

Objective Response Rate (ORR)

Timeframe: through study completion, an average of 1 year

Trial details

NCT IDNCT07512674

SponsorSir Run Run Shaw Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12

View on ClinicalTrials.gov More Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis trials